GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (STU:23I) » Definitions » Shiller PE Ratio

Intra-Cellular Therapies (STU:23I) Shiller PE Ratio : (As of Sep. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Intra-Cellular Therapies Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Intra-Cellular Therapies Shiller PE Ratio Historical Data

The historical data trend for Intra-Cellular Therapies's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Shiller PE Ratio Chart

Intra-Cellular Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Intra-Cellular Therapies Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Intra-Cellular Therapies's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intra-Cellular Therapies's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's Shiller PE Ratio falls into.



Intra-Cellular Therapies Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Intra-Cellular Therapies's E10 for the quarter that ended in Jun. 2024 is calculated as:

For example, Intra-Cellular Therapies's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.149/132.5538*132.5538
=-0.149

Current CPI (Jun. 2024) = 132.5538.

Intra-Cellular Therapies Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201409 -0.171 100.428 -0.226
201412 -0.422 99.070 -0.565
201503 -0.665 99.621 -0.885
201506 -0.544 100.684 -0.716
201509 -0.811 100.392 -1.071
201512 -0.615 99.792 -0.817
201603 -0.575 100.470 -0.759
201606 -0.632 101.688 -0.824
201609 -0.624 101.861 -0.812
201612 -0.607 101.863 -0.790
201703 -0.580 102.862 -0.747
201706 -0.365 103.349 -0.468
201709 -0.445 104.136 -0.566
201712 -0.473 104.011 -0.603
201803 -0.527 105.290 -0.663
201806 -0.582 106.317 -0.726
201809 -0.651 106.507 -0.810
201812 -0.659 105.998 -0.824
201903 -0.558 107.251 -0.690
201906 -0.602 108.070 -0.738
201909 -0.572 108.329 -0.700
201912 -0.666 108.420 -0.814
202003 -0.661 108.902 -0.805
202006 -0.852 108.767 -1.038
202009 -0.671 109.815 -0.810
202012 -0.625 109.897 -0.754
202103 -0.546 111.754 -0.648
202106 -0.706 114.631 -0.816
202109 -0.808 115.734 -0.925
202112 -0.929 117.630 -1.047
202203 -0.708 121.301 -0.774
202206 -0.870 125.017 -0.922
202209 -0.576 125.227 -0.610
202212 -0.425 125.222 -0.450
202303 -0.430 127.348 -0.448
202306 -0.415 128.729 -0.427
202309 -0.234 129.860 -0.239
202312 -0.275 129.419 -0.282
202403 -0.147 131.776 -0.148
202406 -0.149 132.554 -0.149

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Intra-Cellular Therapies  (STU:23I) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Intra-Cellular Therapies Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Intra-Cellular Therapies Business Description

Traded in Other Exchanges
Address
430 East 29th Street, New York, NY, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies Headlines

No Headlines